NCT03077490

Brief Summary

Comparison of single versus multicenter outcomes for pelvic organ prolapse repair using a mesh-capturing device (The Uphold™ Vaginal Support System for apical and vaginal wall prolapse - Boston Scientific). 1-2 years follow up study comprison of 112 vs 207 patients.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
319

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2015

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 4, 2015

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2016

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

February 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 13, 2017

Completed
Last Updated

October 23, 2019

Status Verified

October 1, 2019

Enrollment Period

1.1 years

First QC Date

February 1, 2017

Last Update Submit

October 21, 2019

Conditions

Keywords

Pelvic organ prolapsetransvaginal meshcomplications

Outcome Measures

Primary Outcomes (2)

  • The rate of immediate complications

    Serious surgical complications are categorized as any surgical event which is potentially life-threatening related to the surgical procedure including: internal organ perforation (or other injury), bleeding in excess of 1000 mL.

    From operation start to hospital discharge, assessed for an estimated total of days (1-7 days).

  • Rate of delayed complications

    Adverse events during follow-up which requires re-hospitalisation or surgical re-intervention.

    From hospital discharge and up to 2 years at single center and 1 year at multicenter

Secondary Outcomes (7)

  • Anatomical outcomes

    2 years vs 1 year

  • Subjective outcomes and sexual function

    2 years vs 1 year

  • Ultrasound mapping of mesh position in the pelvic floor and correlation to anatomical and subjective outcomes and sexual function

    5, 7, 10 years

  • Measurement of Pain by patient self-reporting Visual analogue scale (VAS-scale)

    Changes from baseline, 2, 5 and 10 years after surgery

  • Measurement of urinary incontinence by patient self-reporting Visual analogue scale (VAS-scale)

    Changes from baseline, 2, 5 and 10 years after surgery

  • +2 more secondary outcomes

Study Arms (1)

Single center vs. multicenter

Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.

Device: Transvaginal mesh Uphold TM Vaginal Support SystemDevice: Transvaginal mesh Uphold TM Vaginal Support System.

Interventions

Single center vs. multicenter

Eligibility Criteria

Age18 Years - 90 Years
Sexfemale(Gender-based eligibility)
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

112 patients from single center compared to 207 patients from 24 different centers

You may qualify if:

  • Posthysterectomy prolapse of the vaginal apex, with or without cystocele, where the vaginal apex descends at least 50% of the total vaginal length
  • Uterine prolapse, with or without cystocele, where the leading edge of the cervix descends at least 50% of the total vaginal length and TVL minus point C= ≤ 2 cm
  • Prolapse specific pelvic symptom of pelvic heaviness and/or vaginal bulging
  • Reproductive years in the past (biologically or reproductive decision)
  • Being able to make an informed consent on participation
  • Physically and cognitively capable of participating in the required follow-up

You may not qualify if:

  • Posthysterectomy prolapse of the vaginal apex where the vaginal apex descends less than 50% of the total vaginal length regardless of whether a cystocele is present or not
  • Uterine prolapse, with or without cystocele, where the leading edge of the cervix descends less than 50% of the total vaginal length
  • If cervix elongation is present corresponding to: TVL minus point C= \>2 cm.
  • If prolapse specific pelvic symptoms of pelvic heaviness and/or vaginal bulging are not present
  • Previous or current pelvic organ cancer (regardless of treatment)
  • Severe rheumatic disease
  • Insulin treated diabetes mellitus
  • Connective tissue disorders (SLE, Sjögrens syndrome, Marfans syndrome, Ehlers Dahnlos, collagenosis, polymyositis eller rheumatic myalgia)
  • Current systemic steroid treatment
  • Other clinically relevant pelvic disorders for which surgery is indicated including stress urinary incontinence, cervix elongation and posterior prolapse
  • Decision to perform prolapse surgery using other medical devices/mesh

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pelvic Organ Prolapse

Condition Hierarchy (Ancestors)

ProlapsePathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior consultant, MD, PhD

Study Record Dates

First Submitted

February 1, 2017

First Posted

March 13, 2017

Study Start

March 4, 2015

Primary Completion

March 30, 2016

Study Completion

February 1, 2017

Last Updated

October 23, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share